Literature DB >> 23498041

Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services.

Mweete Debra Nglazi1, Richard Kaplan, Judy Caldwell, Neshaan Peton, Stephen D Lawn, Robin Wood, Linda-Gail Bekker.   

Abstract

BACKGROUND: Delivery of integrated care for patients with HIV-associated TB is challenging. We assessed the uptake and timing of antiretroviral treatment (ART) among eligible patients attending a primary care service with co-located ART and TB clinics.
METHODS: In a retrospective cohort study, all HIV-associated TB patients (≥18 years old) who commenced TB treatment in 2010 were included. Data were analysed using basic descriptive statistics and log-binomial regression analysis.
RESULTS: Of a total of 497 patients diagnosed with HIV-associated TB, 274 were eligible to start ART for the first time (median CD4 count, 159 cells/µl). ART was started during TB treatment by 220 (80.3%) patients. Among the 54 (19.7%) who did not start ART, 23 (42.6%) were either lost to follow-up (LTFU) or died before enrolling for ART; 12 (22.2%) were either LTFU or died after enrolling but before starting ART; 5 (9.3%) were transferred out; and 14 (25.9%) only started ART after completion of TB treatment. The median delay between starting TB treatment and starting ART was 51 days (IQR 29 - 77). Overall, only 58.6% of patients started ART within 8 weeks of TB treatment, and 12.7% of those with CD4 counts <50 cells/µl started ART within 2 weeks.
CONCLUSIONS: In a setting with co-located TB and ART clinics, delays to starting ART were substantial, and one-fifth of eligible patients did not start ART during TB treatment. Co-location of services alone is insufficient to permit timely initiation of ART; further measures need to be implemented to facilitate integrated treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23498041      PMCID: PMC3960570          DOI: 10.7196/samj.6024

Source DB:  PubMed          Journal:  S Afr Med J


  9 in total

1.  Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa.

Authors:  Amrita Daftary; Nesri Padayatchi
Journal:  AIDS Care       Date:  2012-04-24

2.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Authors:  Diane V Havlir; Michelle A Kendall; Prudence Ive; Johnstone Kumwenda; Susan Swindells; Sarojini S Qasba; Anne F Luetkemeyer; Evelyn Hogg; James F Rooney; Xingye Wu; Mina C Hosseinipour; Umesh Lalloo; Valdilea G Veloso; Fatuma F Some; N Kumarasamy; Nesri Padayatchi; Breno R Santos; Stewart Reid; James Hakim; Lerato Mohapi; Peter Mugyenyi; Jorge Sanchez; Javier R Lama; Jean W Pape; Alejandro Sanchez; Aida Asmelash; Evans Moko; Fred Sawe; Janet Andersen; Ian Sanne
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

3.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  Tuberculosis.

Authors:  Stephen D Lawn; Alimuddin I Zumla
Journal:  Lancet       Date:  2011-03-21       Impact factor: 79.321

5.  Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.

Authors:  Stephen D Lawn; Lucy Campbell; Richard Kaplan; Andrew Boulle; Morna Cornell; Bernhard Kerschberger; Carl Morrow; Francesca Little; Matthias Egger; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

6.  Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.

Authors:  Dominique J Pepper; Suzaan Marais; Robert J Wilkinson; Feriyl Bhaijee; Virginia De Azevedo; Graeme Meintjes
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

7.  Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.

Authors:  Stephen D Lawn; Lucy Campbell; Richard Kaplan; Francesca Little; Carl Morrow; Robin Wood
Journal:  BMC Infect Dis       Date:  2011-09-30       Impact factor: 3.090

8.  Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport.

Authors:  Rony Zachariah; Anthony David Harries; Marcel Manzi; Patrick Gomani; Roger Teck; Mit Phillips; Peter Firmenich
Journal:  PLoS One       Date:  2006-12-27       Impact factor: 3.240

Review 9.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

  9 in total
  7 in total

1.  Successful Tuberculosis Treatment Outcomes among HIV/TB Coinfected Patients Down-Referred from a District Hospital to Primary Health Clinics in Rural South Africa.

Authors:  Karen B Jacobson; Anthony P Moll; Gerald H Friedland; Sheela V Shenoi
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

2.  Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol.

Authors:  Kogieleum Naidoo; Santhanalakshmi Gengiah; Nonhlanhla Yende-Zuma; Nesri Padayatchi; Pierre Barker; Andrew Nunn; Priashni Subrayen; Salim S Abdool Karim
Journal:  Implement Sci       Date:  2017-11-13       Impact factor: 7.327

3.  Gender difference in mortality among pulmonary tuberculosis HIV co-infected adults aged 15-49 years in Kenya.

Authors:  Rose J Kosgei; Steven Callens; Peter Gichangi; Marleen Temmerman; Anne-Beatrice Kihara; Gathara David; Eunice Nyaboe Omesa; Enos Masini; E Jane Carter
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

4.  Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi.

Authors:  Hannock Tweya; Anne Ben-Smith; Mike Kalulu; Andreas Jahn; Wingston Ng'ambi; Elizabeth Mkandawire; Layout Gabriel; Sam Phiri
Journal:  BMC Public Health       Date:  2014-02-20       Impact factor: 3.295

5.  Biomedical research, a tool to address the health issues that affect African populations.

Authors:  Emmanuel Peprah; Ambroise Wonkam
Journal:  Global Health       Date:  2013-10-21       Impact factor: 4.185

6.  High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland.

Authors:  Ishani Pathmanathan; Munyaradzi Pasipamire; Sherri Pals; E Kainne Dokubo; Peter Preko; Trong Ao; Sikhathele Mazibuko; Janet Ongole; Themba Dhlamini; Samson Haumba
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

7.  Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria.

Authors:  B Odume; I Pathmanathan; S Pals; K Dokubo; D Onotu; O Obinna; D Anand; J Okuma; E Okpokoro; S Dutt; E Ekong; N Chukwurah; P Dakum; H Tomlinson
Journal:  Univers J Public Health       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.